Clinical Trial Update: Caspofungin for the Treatment of Non-blood Candida Infections (0991-045) [Phase 2]

View source ↗

Summary

Completed Phase 2 trial evaluating caspofungin for the treatment of non-blood Candida infections, sponsored by Merck Sharp & Dohme LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Candidiasis

Drugs mentioned

• Cancidas (caspofungin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Candidiasis | Phase 2 | Status: COMPLETED